BTMDMEDIUM SIGNALFINANCIAL10-K

BTMD shows declining cash generation and reduced shareholder returns alongside improved balance sheet positioning through liability reduction.

The company's operating cash flow declined 22% while dividends and share buybacks were substantially reduced, indicating either operational headwinds or a shift toward capital conservation. However, the meaningful reduction in total liabilities and improvement in stockholders' equity suggests active balance sheet optimization efforts are underway.

Comparing 2026-03-13 vs 2025-03-14View on EDGAR →
FINANCIAL ANALYSIS

BTMD's financial profile shows mixed signals with operating cash flow declining to $35.2M and cash reserves dropping to $24.1M, while the company pulled back on shareholder returns through reduced dividends and buybacks. However, the balance sheet strengthened notably with total liabilities falling 30% to $158.0M and stockholders' equity improving by $47.4M, suggesting debt reduction or restructuring activities. The increased inventory levels combined with reduced cash generation may indicate either business expansion efforts or working capital management challenges.

FINANCIAL STATEMENT CHANGES
Dividends Paid
Cash Flow
-63.6%
$4.7M→$1.7M

Dividends cut 63.6% — significant signal of cash flow stress or capital reallocation priorities.

Stockholders Equity
Balance Sheet
+44.7%
-$105.9M→-$58.5M

Equity base grew 44.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Share Buybacks
Cash Flow
-39.9%
$5.6M→$3.4M

Buyback activity reduced 39.9% — capital being redeployed elsewhere or cash conservation underway.

Cash & Equivalents
Balance Sheet
-38.7%
$39.3M→$24.1M

Cash declined 38.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
-29.6%
$224.6M→$158.0M

Liabilities reduced 29.6% — deleveraging improves balance sheet strength and financial flexibility.

Inventory
Balance Sheet
+28.4%
$14.8M→$19.1M

Inventory built 28.4% — monitor whether demand supports this build or if write-downs may follow.

Operating Cash Flow
Cash Flow
-22.2%
$45.2M→$35.2M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Capital Expenditure
Cash Flow
-22%
$6.4M→$5.0M

Capex reduced 22% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
-19.8%
$68.1M→$54.7M

Current assets declined 19.8% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
-12.7%
$51.5M→$45.0M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-13
PRIOR — 2025-03-14
ADDED
As of March 11, 2026, the registrant had 32,300,867 shares of Class A common stock, $0.0001 par value per share, outstanding and 7,249,879 shares of Class V voting stock, $0.0001 par value per share, outstanding.
Failure by outsourcing facilities and dietary supplement contract manufacturers to meet applicable standards or, in the case of third-party facilities, to meet their obligations to us, could materially harm our reputation, business, financial condition and results of operations.
We and Biote-certified practitioners and Biote-partnered clinics are reliant on AnazaoHealth Corporation, Right Value Drug Stores, LLC, and Biote-owned Asteria Health to support the compounding of bioidentical hormones for prescribers.
If we are not able to avoid infringement of third-party intellectual property rights, our ability to commercialize products may be limited unless we secure a license to such rights.
We teach clinicians how to identify early indicators of hormone-related aging conditions, and we believe we are the top practitioner educators by virtue of our experience over 14 years, with approximately six million hormone optimization procedures performed by Biote-certified practitioners, including approximately 400,000 active 5 patients, in each case, as of December 31, 2025.
+7 more — sign up free →
REMOVED
As of March 12, 2025, the registrant had 33,073,277 shares of Class A common stock, $0.0001 par value per share, outstanding and 21,636,975 shares of Class V voting stock, $0.0001 par value per share, outstanding.
Outsourcing facilities that produce bioidentical hormone pellets that we offer training on in the Biote Method and failure by those parties to adequately perform their obligations could harm our business.
We and Biote-certified practitioners and Biote-partnered clinics are reliant on AnazaoHealth Corporation, Right Value Drug Stores, LLC, and F.H.
( Asteria Health ) to support the manufacturing of bioidentical hormones for prescribers.
We have limited history of providing the Biote Method to practitioners in the hormone optimization space, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →